Central Bank & Trust’s Bristol-Myers Squibb BMY Stock Holding History

Central Bank & Trust’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,589	Closed	-$66K	–	209
2024 Q2	$66K	Sell	1,589 -4,983	-76%	-$223K	0.01%	242
2024 Q1	$356K	Hold	6,572	–	–	0.05%	151
2023 Q4	$337K	Sell	6,572 -1,534	-19%	-$80.5K	0.05%	152
2023 Q3	$470K	Buy	8,106 +74	+0.9%	+$4.53K	0.08%	130
2023 Q2	$514K	Hold	8,032	–	–	0.09%	131
2023 Q1	$557K	Sell	8,032 -1,197	-13%	-$84.4K	0.1%	128
2022 Q4	$664K	Buy	9,229 +70	+0.8%	+$5.28K	0.13%	116
2022 Q3	$651K	Sell	9,159 -4,619	-34%	-$335K	0.14%	113
2022 Q2	$1.06M	Sell	13,778 -1,222	-8%	-$93.1K	0.22%	86
2022 Q1	$1.09M	Sell	15,000 -1,859	-11%	-$125K	0.17%	93
2021 Q4	$1.05M	Sell	16,859 -311	-2%	-$18.2K	0.16%	95
2021 Q3	$1.02M	Sell	17,170 -524	-3%	-$34.5K	0.17%	92
2021 Q2	$1.18M	Sell	17,694 -4,093	-19%	-$267K	0.19%	86
2021 Q1	$1.38M	Sell	21,787 -3,042	-12%	-$189K	0.23%	81
2020 Q4	$1.54M	Sell	24,829 -624	-2%	-$38.4K	0.27%	78
2020 Q3	$1.53M	Sell	25,453 -7,297	-22%	-$439K	0.29%	77
2020 Q2	$1.93M	Buy	32,750 +545	+2%	+$32.6K	0.38%	67
2020 Q1	$1.79M	Sell	32,205 -105	-0.3%	-$6.42K	0.43%	62
2019 Q4	$2.07M	Buy	32,310 +28,489	+746%	+$1.63M	0.41%	63
2019 Q3	$194K	Hold	3,821	–	–	0.04%	135
2019 Q2	$173K	Sell	3,821 -42	-1%	-$1.96K	0.04%	142
2019 Q1	$184K	Sell	3,863 -125	-3%	-$6.23K	0.04%	143
2018 Q4	$207K	Hold	3,988	–	–	0.05%	122
2018 Q3	$248K	Hold	3,988	–	–	0.06%	121
2018 Q2	$221K	Sell	3,988 -117	-3%	-$6.32K	0.06%	124
2018 Q1	$260K	Hold	4,105	–	–	0.06%	120
2017 Q4	$252K	Hold	4,105	–	–	0.06%	126
2017 Q3	$262K	Hold	4,105	–	–	0.07%	124
2017 Q2	$229K	Sell	4,105 -962	-19%	-$52.3K	0.06%	127
2017 Q1	$275K	Buy	5,067 +139	+3%	+$7.62K	0.07%	124
2016 Q4	$288K	Sell	4,928 -288	-6%	-$15.7K	0.08%	123
2016 Q3	$281K	Sell	5,216 -60	-1%	-$3.85K	0.08%	117
2016 Q2	$388K	Sell	5,276 -1,363	-21%	-$96.3K	0.11%	98
2016 Q1	$424K	Hold	6,639	–	–	0.12%	95
2015 Q4	$457K	Buy	6,639 +154	+2%	+$10.2K	0.13%	99
2015 Q3	$384K	Sell	6,485 -587	-8%	-$37.2K	0.13%	94
2015 Q2	$471K	Buy	7,072 +783	+12%	+$51.6K	0.15%	95
2015 Q1	$405K	Sell	6,289 -619	-9%	-$38.8K	0.13%	96
2014 Q4	$408K	Buy	6,908 +1,032	+18%	+$58.2K	0.14%	97
2014 Q3	$301K	Sell	5,876 -1,199	-17%	-$59.9K	0.11%	115
2014 Q2	$376K	Buy	7,075 +200	+3%	+$9.86K	0.15%	99
2014 Q1	$357K	Sell	6,875 -200	-3%	-$10.6K	0.14%	100
2013 Q4	$376K	Sell	7,075 -6,454	-48%	-$329K	0.15%	99
2013 Q3	$626K	Sell	13,529 -14,870	-52%	-$653K	0.28%	84
2013 Q2	$1.27M	Buy	+28,399	New	+$1.23M	0.6%	61

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Central Bank & Trust's BMY Position: Q3 2024 in Review

Central Bank & Trust sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 1,589 shares — an estimated $66K sold.

Central Bank & Trust first reported a position in BMY in Q2 2013 and held it in 45 quarters. The position peaked at $2.07M in Q4 2019. 2,258 funds tracked by Wall St. Rank hold BMY as of Q3 2024.

Central Bank & Trust reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
Central Bank & Trust sold 1,589 Bristol-Myers Squibb shares in Q3 2024, an estimated $66K.
Central Bank & Trust first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 45 quarters.
Central Bank & Trust's Bristol-Myers Squibb position peaked at $2.07M in Q4 2019.
2,258 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.

Based on Central Bank & Trust's 13F filing for Q3 2024, filed 30 Oct 2024.